亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

南京肽業(yè)生物科技有限公司多肽  

多肽,氨基酸

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 122384-88-7|糖尿病相關(guān)肽|胰島淀粉樣肽
122384-88-7|糖尿病相關(guān)肽|胰島淀粉樣肽
單價 面議對比
詢價 暫無
發(fā)貨 江蘇付款后3天內(nèi)
品牌 南京肽業(yè)
過期 長期有效
更新 2020-11-05 13:59
 
詳細(xì)信息

中文名稱:糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原)

中文同義詞:糊精肽;糖尿病相關(guān)肽(胰島淀粉樣肽),≥97%(HPLC);糖尿病相關(guān)肽(胰島淀粉樣肽)(抗原);糖尿病相關(guān)肽(胰島淀粉樣肽)(抗體);安林肽;糖尿病相關(guān)肽(胰島淀粉樣肽)

英文名稱:AMYLIN,HUMAN

英文同義詞:KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH2(DISULFIDEBRIDGE:2-7);LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAChemicalbookL-HIS-SER-SER-ASN-ASN-PHE-GLY-ALA-ILE-LEU-SER-SER-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2;DIABETESASSOCIATEDPEPTIDEAMIDEHUMAN;DIABETES-ASSOCIATEDPEPTIDE(DAP)AMIDE,HUMAN;DIABETES-ASSOCIATEDPEPTIDEHUMAN;DAP(HUMAN);DAPAMIDE,HUMAN;DAP

CAS號:122384-88-7

分子式:C8H17O3*

分子量:161.21878


©2025 南京肽業(yè)生物科技有限公司多肽 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:5131  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |